As Cytokinetics’ aficamten awaits approval decisions from regulators in the U.S. and China, Sanofi has picked up China rights to…

The failure of a myeloid leukemia drug in a phase 3 trial in China isn’t a shock to Apollomics, which…

A phase 3 trial of Novo Nordisk’s next-generation obesity prospect CagriSema has failed to achieve the level of weight loss…

Idorsia’s plans to sell its hypertension drug Tryvio have faced a speedbump, even as the biotech ploughs ahead with around…

Aadi Bioscience has rebooted its operations, transforming from a commercial business into a preclinical biotech by offloading its approved product and…

The FDA has denied Zealand Pharma’s approval bid for glepaglutide—a possible challenger to Takeda’s Gattex—in short bowel syndrome (SBS), citing…

Pyxis Oncology is shelving a clinical-stage monoclonal antibody to focus on its lead antibody-drug conjugate (ADC) after sharing preliminary results…

To develop RNA medicines targeting a proprietary bundle of tumor antigens, Epitopea is tapping nucleic acid delivery specialist Genevant Sciences…

Welcome to this week's Chutes & Ladders, our roundup of significant leadership hirings, firings and retirings across the industry. Please…

Omeros is putting up its monoclonal antibody up for FDA approval—again. This time, the resubmission will be based on a…